


RealRate

PHARMACEUTICAL 2018

PROCYON

PROCYON CORP Rank 29 of 349







RealRate

PHARMACEUTICAL 2018

PROCYON CORP Rank 29 of 349

The relative strengths and weaknesses of PROCYON CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PROCYON CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 919% points. The greatest weakness of PROCYON CORP is the variable Other Expenses, reducing the Economic Capital Ratio by 540% points.

The company's Economic Capital Ratio, given in the ranking table, is 162%, being 439% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	1,592
Cost of Goods Sold	0
Intangible Assets	17
Liabilities, Current	440
Liabilities, Non-Current	0
Other Assets	607
Other Compr. Net Income	0
Other Expenses	2,846
Other Liabilities	2.1
Other Net Income	-0.98
Property and Equipment	514
Research and Development	0
Revenues	4,012
Selling, General and Administrative Expense	1,153

Output Variable	Value in 1000 USD
Assets	2,730
Liabilities	442
Expenses	3,999
Stockholders Equity	2,288
Net Income	12
Comprehensive Net Income	12
Economic Capital Ratio	162%

